IUH Trial ChartsDiabetes Threshold5678910Baseline10 Weeks9.07.26.26.95.86.1Average HbA1c (%)Baseline HbA1c (%)7.5n=966.5–7.4n=95<6.5n=47 IUH Trial Charts100%80%60%40%20%0%Percent of users with dosage change93%86%60%57%30%28%100%75%11%6%87%36%93%90%EliminatedReducedInsulinsSulfonylureasSGLT-2 InhibitorsDPP-4 InhibitorsGLP-1 Receptor AgonistsThiazolidinedionesMetforminn=78n=62n=29n=4n=30n=43n=193 IUH Trial ChartsBaseline10 Weeksaverage decrease in triglycerides22%20016018012014010080Time in Virta ClinicAverage triglycerides (mg·dL-¹)185145 IUH Trial Charts01098765Weeks in Virta Clinic43210%-5%-10%-15%Body weight loss-7.2% Diabetes Reversal (1 year) Virta 60% Bariatric Surgery40% Usual Care1% A1c Improments (1 year) Virta-1.3% Usual Care+0.1% Medication Reductions (1 year) 94% A1c at 10 weeks and 1 year Months on Virta 6.0% 0 3 6 9 12 6.5% Diabetes Threshold 7.0% 7.5% 8.0% Average HbA1c 7.6%Baseline 6.5%10 weeks 6.3%1 year Weight loss at 10 weeks and 1 year Months on Virta -15% 0 3 6 9 12 -5% Clinically Significant Weight Loss -10% 0% Weight Loss (as % of starting body weight) -12%1 year -7%10 weeks

Clinical Outcomes

Peer-reviewed research evaluating the effect of the Virta Treatment demonstrates that patients can safely improve health outcomes associated with type 2 diabetes, obesity, atherogenic dyslipidemia, hypertension, and inflammation. By impacting these chronic conditions, the Virta Treatment improves several risk factors for type 2 diabetes and cardiovascular disease.

We’re published in: JMIR Diabetes, Diabetes Therapy, Cardiovascular Diabetology

Type 2 Diabetes

While reducing and eliminating glycemic control medications, Virta patients lowered HbA1c by 1.3% on average after one year and improved insulin resistance measured by HOMA-IR. 60% of patients attained an HbA1c below 6.5% without the use of diabetes-specific medications.

  • Virta
  • Usual Care
Outcomes: Type 2 Diabetes

Obesity

Excess weight represents risk for both type 2 diabetes and cardiovascular disease. Virta patients sustained the loss of 12% of their body weight over the year. The prevalence of class III obesity among participants was reduced from 46% to 20%.

  • Virta
  • Usual Care
Outcomes: Obesity

Atherogenic Dyslipidemia

Characterized by high triglycerides and low HDL-C, atherogenic dyslipidemia is common among patients with insulin resistance and represents increased cardiovascular risk. Virta patients improved both markers, with the TG/HDL-C ratio declining from 4.7 to 3 on average.

  • Virta
  • Usual Care
Outcomes: Atherogenic Dyslipidemia

Hypertension

Elevated blood pressure, especially in the presence of additional risk factors, increases cardiovascular risk. Virta patients reduced blood pressure and the need for antihypertensive medication, especially diuretics.

  • Virta
  • Usual Care

Inflammation

Inflammation is a common underlying factor in obesity, insulin resistance, hypertension, and cardiovascular disease. C-reactive protein and white blood cell count, common markers of inflammation, were significantly reduced in Virta patients with type 2 diabetes.

  • Virta
  • Usual Care
Outcomes: Inflammation

Safety

A common concern in the treatment of type 2 diabetes is hypoglycemia. In our clinical trial, no hypoglycemic events requiring assistance were reported. Additionally, treatment at Virta resulted in neutral or positive effects on markers of kidney and liver function.

  • Virta
  • Usual Care
Outcomes: Safety

Cardiovascular Risk Markers

10-year ASCVD risk score improves after one year of the Virta Treatment. Most lipid and lipoprotein risk markers improved or were unaffected; an undesirable change was observed in one marker.

  • Virta
  • Usual Care
Outcomes: Cardiovascular

Outcomes above were reported in Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Advancing Science and Medicine

Virta Health Research is committed to improving patient health outcomes by advancing the understanding of chronic metabolic conditions and how to best treat them, while providing evidence to inform clinicians and patients in their care decisions.

Peer-reviewed Papers

1-year Outcomes

Sustainability of improved health outcomes

Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Therapy. 2018; 9(2): 583-612. doi: 10.1007/s13300-018-0373-9

After one year of treatment, patients who chose Virta improved glycemic control and markers of other chronic conditions. Tight glycemic control (HbA1c <6.5%) was achieved in the majority of participants with less medications, while losing weight, and without severe hypoglycemic events requiring assistance. Triglycerides, HDL-C, blood pressure, the need for diuretic medications, liver enzymes, and hsCRP also improved.

10-week Outcomes

Rapid impact on type 2 diabetes

McKenzie AL, Hallberg SJ, Creighton BC, et al. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. JMIR Diabetes. 2017; 2(1):e5.

The first investigation of Virta’s novel care model demonstrated that patients could rapidly improve glycemic control through reductions in fasting blood glucose, HbA1c, and medication use after 10 weeks of treatment. Patients lost 7% of their body weight on average and reported less hunger.

Significant impact on cardiovascular risk factors

Bhanpuri NH, Hallberg SJ, Williams PT, McKenzie AL, Ballard KD, Campbell WW, McCarter JP, Phinney SD, Volek JS. Cardiovascular Disease Risk Factor Responses to a Type 2 Diabetes Care Model Including Nutritional Ketosis at One Year: An Open Label, Non-Randomized, Controlled Study. Cardiovasc Diabetol. 2018; 17:56. doi:10.1186/s12933-018-0698-8

For patients living with type 2 diabetes, the risk of cardiovascular disease (CVD) is higher than average and CVD is the leading cause of mortality. There is a need for interventions that mitigate cardiovascular risk in addition to improving glycemic control and markers of insulin resistance. On average, the Virta Treatment improved or had no effect on most markers of cardiovascular risk. For the subset of individuals whose key markers did not improve, the range of responses were similar to those observed in participants who pursued the usual care for their type 2 diabetes.

Ongoing Research

IUH Clinical Trial

In collaboration with researchers and clinicians at IU Health Arnett, the primary purpose of this clinical trial is to demonstrate the therapeutic effects of the intervention over 2 years in participants with type 2 diabetes, prediabetes, and metabolic syndrome.

Secondary purposes include assessing for differences in therapeutic effects of the intervention between patients who self-select onsite vs. web-based education delivery, exploring relationships between change in LDL cholesterol and carotid intima media thickness, and evaluating the sustainability of health outcomes achieved and the economic impact of therapeutic effects over 5 years.

Virta Health Registry for Remote Care of Chronic Conditions

The purpose of this registry is to establish a research data repository, comprised primarily of data generated in the course of clinical care, to conduct research on Virta Health clinical interventions and the chronic conditions present in Virta Health patients.

White Papers

6-month Clinical Trial Outcomes

6-month Clinical Trial Outcomes

Virta aims to address the challenges of sustaining lifestyle and nutritional medicine interventions with ongoing support from a health coach and a physician to continuously personalize their care. In this white paper, we discuss participant retention and health outcomes achieved by participants with type 2 diabetes after six months.

Download PDF

Cardiovascular Benefits

The Cardiovascular Benefits of the Virta Treatment

Cardiovascular disease is the number one cause of morbidity and mortality in patients with type 2 diabetes. Here we discuss the impact of the Virta Treatment on risk factors for cardiovascular disease including hypertension, atherogenic dyslipidemia, LDL partitioning, inflammation, insulin resistance, obesity, liver function, carotid intima media thickness, medications, and composite risk scores. Together these findings suggest near-term and projected long-term improvement in cardiovascular risk.

Download PDF

Virta’s Perspective

Science and Research Blog

Visit the Virta Health blog to learn more about our thoughts on the latest research and hot topics in the field.

Our Research Foundation

We’ve incorporated findings from decades of scientific research and hundreds of studies to develop our novel, patient-centered, comprehensive care model, the Virta Treatment, to improve type 2 diabetes and chronic metabolic conditions.